High-density lipoprotein and coronary heart disease: current and future therapies.
about
Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reductionLow-density lipoprotein cholesterol, apolipoprotein B, and risk of coronary heart disease: from familial hyperlipidemia to genomicsLifestyle interventions for hypertension and dyslipidemia among women of reproductive ageIs prevention a fantasy, or the future of medicine? A panoramic view of recent data, status, and direction in cardiovascular prevention.A pro-atherogenic HDL profile in coronary heart disease patients: an iTRAQ labelling-based proteomic approachHuman plasma lipid modulation in schistosomiasis mansoni depends on apolipoprotein E polymorphismPrimary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.miR-33 links SREBP-2 induction to repression of sterol transporters.Hyperlipidemia medication management in patients admitted for a myocardial infarction.Gene-environment interactions of CETP gene variation in a high cardiovascular risk Mediterranean populationMining the LIPG allelic spectrum reveals the contribution of rare and common regulatory variants to HDL cholesterolCardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute Coronary Syndrome Israeli Surveys data.High density lipoproteins-based therapies for cardiovascular disease.Prevalence and pattern of lipid disorders in Saudi patients with angiographically documented coronary artery disease.Carboxyl terminus of apolipoprotein A-I (ApoA-I) is necessary for the transport of lipid-free ApoA-I but not prelipidated ApoA-I particles through aortic endothelial cellsThe association of common SNPs and haplotypes in CETP gene with HDL cholesterol levels in Latvian populationApolipoprotein A-I and its mimetics for the treatment of atherosclerosis.Relationship of high-density lipoprotein cholesterol with periprocedural myocardial injury following elective percutaneous coronary intervention in patients with low-density lipoprotein cholesterol below 70 mg/dL.High glucose diets shorten lifespan of Caenorhabditis elegans via ectopic apoptosis induction.Effects of niacin on atherosclerosis and vascular function.Simultaneous transfer of cholesterol, triglycerides, and phospholipids to high-density lipoprotein in aging subjects with or without coronary artery diseaseSimvastatin blocks blood-brain barrier disruptions induced by elevated cholesterol both in vivo and in vitro.The High Prevalence of Low HDL-Cholesterol Levels and Dyslipidemia in Rural Populations in Northwestern China.Association of rs5888 SNP in the scavenger receptor class B type 1 gene and serum lipid levels.A nutrient-dense, high-fiber, fruit-based supplement bar increases HDL cholesterol, particularly large HDL, lowers homocysteine, and raises glutathione in a 2-wk trial.High Density Lipoprotein and it's DysfunctionCardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.Orthotopic liver transplantation in an adult with cholesterol ester storage disease.Low HDL cholesterol as a cardiovascular risk factor in rural, urban, and rural-urban migrants: PERU MIGRANT cohort study.Glycation of apoprotein A-I is associated with coronary artery plaque progression in type 2 diabetic patients.Changes in coronary heart disease risk profiles of HIV patients in Zimbabwe over 9 months: a follow-up study.Branched-Chain Amino Acid Levels Are Related with Surrogates of Disturbed Lipid Metabolism among Older Men.Is combined lipid-regulating therapy safe and feasible for the very old patients with mixed dyslipidemia?Predictive and Prognostic Value of High-density Lipoprotein Cholesterol in Young Male Patients with Acute Myocardial Infarction.Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies.Recombinant high-density lipoprotein formulations.Nanobiotechnology applications of reconstituted high density lipoprotein.The facts behind niacin.From treating complex coronary artery disease to promoting cardiovascular health: therapeutic transitions and challenges, 2010-2020.Optimal lipid targets for the new era of cardiovascular prevention.
P2860
Q21246041-A4F90AAC-A8DB-4378-96A7-32FAB6EDCC74Q26853114-EE6582F3-8AD0-48FF-A5D6-3B23DC3C38BEQ27016624-871645A8-D374-4752-B05C-F0A4D2A8A8F7Q30397875-89172791-FFC7-46D6-B401-83C478CB65ECQ33655192-4BCC42FC-0F11-4AA0-A70B-96140C48E20EQ33933106-6DEA7393-0907-4630-90AE-ADE7E9D1F7A4Q33972551-A5535FCA-AA97-426B-8A2E-EDB8A1F9F768Q33981907-C7C1A7A8-675F-4024-B793-49BCD0FBDB3FQ34045514-64432659-8EF7-41E2-B50E-7A8488F2312BQ34053189-B4780F1B-1D4A-43DD-A91C-4FFEB837F3E7Q34102781-91D67604-1AF7-4F33-8505-99BF3F813E25Q34241802-CFA7EF72-6FD4-497B-98AA-0427248CB930Q34313937-507F442C-A1DC-453A-AE8A-C4A60501F09AQ34425439-E1460607-9AD7-4131-89EB-1DF6597D2889Q34624089-E282603F-F2CF-4061-9808-EEC20F8BFC5EQ34723286-E69BC9CC-7549-4939-819B-6B22F10E14C4Q34781496-0E9177DA-F6A4-4A28-974E-5C9E8F2C48DDQ35088129-EF4F3807-E0DC-4F94-AF54-430FED9CE171Q35097720-8CE574D5-B835-4B60-9655-495A41B13D5DQ35132366-C1537723-1000-4559-8513-9223A741CD93Q35188359-E284930A-0D0F-42C9-B54C-59428BC1EA03Q35810686-515E2551-E2C3-4310-8179-02E9133535CAQ35861948-107AC12B-58E4-4DB7-B7ED-D347B1090316Q36082750-12D32599-C67D-430C-A9AB-B9622C425690Q36117465-EB561C6C-1EA5-4644-8DDC-FE80AAB3CFCDQ36150462-6F5B8A5C-D260-4FA1-9F14-7DABED1447BCQ36419283-64B271CD-D2AF-41C0-8F50-9769F03A41D1Q36590918-7B786B5C-DA19-4406-9485-132C4E57BF67Q36636757-30CEF759-A158-47F7-9D8F-42ECECAB06E1Q36782743-7E9BD1E0-7BD1-4D9F-A3B6-10A22BE60501Q37381433-BAB210E9-9E98-4D62-8343-F033C251CC2FQ37438100-35AEB04C-8198-4FFA-94C8-276FBE9BE86BQ37466722-9AE88730-57C2-4793-AAB5-975AA75E87DAQ37572433-768E6581-E3EA-4E45-A0C9-E6F8C35DB7F6Q37695401-E2C8DFFD-5322-4930-8A7D-286328F8AFA7Q37807911-95E3D3CA-5DA0-4A44-82DB-4EB5384EF1E1Q37814488-9FFC0652-A335-474E-9DEE-B90F945F1A92Q37926768-8F767187-9C4C-42CB-BE98-3501FB4C2631Q37928904-D9BB7C24-C7B2-414F-8886-F1E743146618Q38006740-C67D5172-ECC8-44A0-907A-A1D30D971B53
P2860
High-density lipoprotein and coronary heart disease: current and future therapies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
High-density lipoprotein and coronary heart disease: current and future therapies.
@en
High-density lipoprotein and coronary heart disease: current and future therapies.
@nl
type
label
High-density lipoprotein and coronary heart disease: current and future therapies.
@en
High-density lipoprotein and coronary heart disease: current and future therapies.
@nl
prefLabel
High-density lipoprotein and coronary heart disease: current and future therapies.
@en
High-density lipoprotein and coronary heart disease: current and future therapies.
@nl
P1476
High-density lipoprotein and coronary heart disease: current and future therapies
@en
P2093
Christopher P Cannon
Kausik K Ray
P304
P356
10.1016/J.JACC.2010.01.008
P407
P577
2010-03-01T00:00:00Z